Clinical Trial Update: A Study on the Long Term Survivals in an Expand Access Program (EAP) of Iressa [Phase 4]

View source ↗

Summary

A completed Phase 4 study in an expanded access program evaluating long-term survival in non-small cell lung cancer patients treated with Iressa (gefitinib).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Iressa (gefitinib)

Snippet

Sponsor: AstraZeneca | Conditions: Non-small Cell Lung Cancer | Phase 4 | Status: COMPLETED